Burkitt's tumor in the United States

Martin H. Cohen, John M. Bennett, Costan W. Berard, John L. Ziegler, Charles L. Vogel, John N. Sheagren, Paul P. Carbone

Research output: Contribution to journalArticle

75 Scopus citations

Abstract

Twenty American patients with tumors histologically and histochemically identical to African Burkitt's tumor have been identified. These patients have been studied with regard to diagnostic criteria and clinicopathologic features of disease. In the 10 most recent patients, nontumor‐specific immune factors which might influence survival and responsiveness to standardized chemotherapy with cyclophosphamide have also been evaluated. Clinically, abdominal tumors dominate the clinical picture with jaw tumors second in frequency. Studies of immune factors revealed normal or only slightly deviated from normal immunologic capacity except for 3 patients who showed marked decrease in serum IgG. The tumor was found to be extremely sensitive to cyclophosphamide with high dose intermittent therapy providing the best results.

Original languageEnglish (US)
Pages (from-to)1259-1272
Number of pages14
JournalCancer
Volume23
Issue number6
DOIs
StatePublished - Jun 1969

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Burkitt's tumor in the United States'. Together they form a unique fingerprint.

  • Cite this

    Cohen, M. H., Bennett, J. M., Berard, C. W., Ziegler, J. L., Vogel, C. L., Sheagren, J. N., & Carbone, P. P. (1969). Burkitt's tumor in the United States. Cancer, 23(6), 1259-1272. https://doi.org/10.1002/1097-0142(196906)23:6<1259::AID-CNCR2820230604>3.0.CO;2-C